Stevanato Group S.p.a. (STVN)

$18.73

-0.24

(-1.27%)▲

Market is closed - opens 7 PM, 08 Oct 2024

Performance

  • $18.71
    $19.33
    $18.73
    downward going graph

    0.11%

    Downside

    Day's Volatility :3.21%

    Upside

    3.1%

    downward going graph
  • $16.56
    $35.56
    $18.73
    downward going graph

    11.59%

    Downside

    52 Weeks Volatility :53.43%

    Upside

    47.33%

    downward going graph

Returns

PeriodStevanato Group S.p.a.Sector (Health Care)Index (Russel 2000)
3 Months
2.32%
5.0%
0.0%
6 Months
-34.31%
5.9%
0.0%
1 Year
-42.67%
16.6%
0.0%
3 Years
-23.2%
18.9%
-21.4%

Highlights

Market Capitalization
5.5B
Book Value
$4.85
Dividend Share
0.053
Dividend Yield
0.29%
Earnings Per Share (EPS)
0.51
PE Ratio
39.22
PEG Ratio
3.57
Wall Street Target Price
26.31
Profit Margin
11.27%
Operating Margin TTM
12.6%
Return On Assets TTM
5.3%
Return On Equity TTM
10.31%
Revenue TTM
1.1B
Revenue Per Share TTM
4.07
Quarterly Revenue Growth YOY
1.7000000000000002%
Gross Profit TTM
319.8M
EBITDA
240.2M
Diluted Eps TTM
0.51
Quarterly Earnings Growth YOY
-0.42
EPS Estimate Current Year
0.54
EPS Estimate Next Year
0.63
EPS Estimate Current Quarter
0.11
EPS Estimate Next Quarter
0.15

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Stevanato Group S.p.a.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
11
11
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 40.47%

Current $18.73
Target $26.31

Company Financials

FY19Y/Y Change
Revenue
596.2M
-
Net Income
43.6M
-
Net Profit Margin
7.31%
-
FY20Y/Y Change
Revenue
805.2M
↑ 23.39%
Net Income
95.5M
↑ 100.28%
Net Profit Margin
11.86%
↑ 4.55%
FY21Y/Y Change
Revenue
954.0M
↑ 27.47%
Net Income
151.8M
↑ 71.08%
Net Profit Margin
15.92%
↑ 4.06%
FY22Y/Y Change
Revenue
1.0B
↑ 16.57%
Net Income
151.2M
↑ 6.35%
Net Profit Margin
14.52%
↓ 1.4%
FY23Y/Y Change
Revenue
1.2B
↑ 8.07%
Net Income
158.9M
↑ 1.95%
Net Profit Margin
13.7%
↓ 0.82%
Q1 FY23Q/Q Change
Revenue
254.7M
↓ 18.52%
Net Income
30.3M
↓ 41.58%
Net Profit Margin
11.88%
↓ 4.68%
Q2 FY23Q/Q Change
Revenue
276.9M
↑ 7.27%
Net Income
37.1M
↑ 21.14%
Net Profit Margin
13.41%
↑ 1.53%
Q3 FY23Q/Q Change
Revenue
289.7M
↑ 6.31%
Net Income
40.5M
↑ 10.67%
Net Profit Margin
13.96%
↑ 0.55%
Q4 FY23Q/Q Change
Revenue
340.8M
↑ 15.11%
Net Income
49.3M
↑ 19.36%
Net Profit Margin
14.48%
↑ 0.52%
Q1 FY24Q/Q Change
Revenue
258.0M
↓ 24.02%
Net Income
20.4M
↓ 58.4%
Net Profit Margin
7.93%
↓ 6.55%
Q2 FY24Q/Q Change
Revenue
260.9M
↑ 9.9%
Net Income
20.6M
↑ 9.63%
Net Profit Margin
7.91%
↓ 0.02%
FY18Y/Y Change
Total Assets
889.1M
-
Total Liabilities
625.9M
-
FY19Y/Y Change
Total Assets
980.3M
↑ 12.87%
Total Liabilities
685.3M
↑ 12.1%
FY20Y/Y Change
Total Assets
1.2B
↑ 9.73%
Total Liabilities
800.1M
↑ 6.66%
FY21Y/Y Change
Total Assets
1.6B
↑ 46.54%
Total Liabilities
652.5M
↓ 12.26%
FY22Y/Y Change
Total Assets
1.8B
↑ 16.99%
Total Liabilities
702.5M
↑ 15.0%
FY23Y/Y Change
Total Assets
2.3B
↑ 24.94%
Total Liabilities
1.0B
↑ 41.57%
Q1 FY23Q/Q Change
Total Assets
1.9B
↑ 5.04%
Total Liabilities
762.7M
↑ 7.36%
Q2 FY23Q/Q Change
Total Assets
2.0B
↑ 3.76%
Total Liabilities
434.4M
↓ 43.8%
Q3 FY23Q/Q Change
Total Assets
2.1B
↑ 6.54%
Total Liabilities
402.8M
↓ 5.79%
Q4 FY23Q/Q Change
Total Assets
2.3B
↑ 7.59%
Total Liabilities
1.0B
↑ 149.06%
Q1 FY24Q/Q Change
Total Assets
2.4B
↑ 6.83%
Total Liabilities
959.9M
↓ 6.02%
Q2 FY24Q/Q Change
Total Assets
2.4B
↓ 0.74%
Total Liabilities
939.8M
↓ 1.11%
FY19Y/Y Change
Operating Cash Flow
47.3M
-
Investing Cash Flow
-82.6M
-
Financing Cash Flow
46.9M
-
FY20Y/Y Change
Operating Cash Flow
189.3M
↑ 265.63%
Investing Cash Flow
-116.9M
↑ 29.26%
Financing Cash Flow
-32.3M
↓ 162.88%
FY21Y/Y Change
Operating Cash Flow
150.7M
↓ 14.36%
Investing Cash Flow
-109.0M
↑ 0.35%
Financing Cash Flow
288.0M
↓ 1060.89%
FY22Y/Y Change
Operating Cash Flow
109.3M
↓ 22.51%
Investing Cash Flow
-257.1M
↑ 151.95%
Financing Cash Flow
-47.1M
↓ 117.46%
Q1 FY23Q/Q Change
Operating Cash Flow
39.7M
↓ 37.8%
Investing Cash Flow
-102.6M
↑ 39.35%
Financing Cash Flow
23.5M
↓ 218.28%
Q2 FY23Q/Q Change
Operating Cash Flow
26.5M
↓ 34.29%
Investing Cash Flow
-104.0M
↑ 0.0%
Financing Cash Flow
-27.6M
↓ 215.45%
Q3 FY23Q/Q Change
Operating Cash Flow
35.8M
↑ 37.3%
Investing Cash Flow
-141.1M
↑ 37.85%
Financing Cash Flow
108.6M
↓ 500.39%

Technicals Summary

Sell

Neutral

Buy

Stevanato Group S.p.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Stevanato Group S.p.a.
Stevanato Group S.p.a.
-7.87%
-34.31%
-42.67%
-23.2%
-3.56%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
0.53%
24.56%
63.66%
42.45%
174.56%
Resmed Inc.
Resmed Inc.
-6.24%
24.62%
59.67%
-8.24%
77.02%
Becton, Dickinson And Company
Becton, Dickinson And Company
0.42%
-1.45%
-10.38%
-1.46%
-4.55%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-1.83%
-24.47%
-22.57%
-29.02%
110.73%
Alcon Ag
Alcon Ag
0.81%
16.03%
28.7%
24.02%
70.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Stevanato Group S.p.a.
Stevanato Group S.p.a.
39.22
39.22
3.57
0.54
0.1
0.05
0.0
4.85
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
82.69
82.69
4.14
6.65
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
33.76
33.76
1.96
7.71
0.23
0.13
0.01
33.11
Becton, Dickinson And Company
Becton, Dickinson And Company
47.84
47.84
1.1
13.11
0.06
0.03
0.02
89.5
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.18
42.18
5.14
6.51
0.2
0.11
0.0
35.49
Alcon Ag
Alcon Ag
43.82
43.82
3.62
3.05
0.05
0.03
0.0
42.35
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Stevanato Group S.p.a.
Stevanato Group S.p.a.
Buy
$5.5B
-3.56%
39.22
11.27%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$173.0B
174.56%
82.69
27.65%
Resmed Inc.
Resmed Inc.
Buy
$34.3B
77.02%
33.76
21.79%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$68.9B
-4.55%
47.84
7.13%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$21.5B
110.73%
42.18
18.25%
Alcon Ag
Alcon Ag
Buy
$48.1B
70.71%
43.82
11.44%

Insights on Stevanato Group S.p.a.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 237.38M → 260.89M (in $), with an average increase of 9.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 18.81M → 20.62M (in $), with an average increase of 8.8% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 63.0% return, outperforming this stock by 104.3%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 42.4% return, outperforming this stock by 65.6%

Institutional Holdings

  • Conestoga Capital Advisors, LLC

    2.26%

  • Neuberger Berman Group LLC

    1.41%

  • T. Rowe Price Investment Management,Inc.

    1.13%

  • Wellington Management Company LLP

    0.80%

  • Jackson Square Partners, LLC

    0.69%

  • Sands Capital Management, LLC

    0.56%

Corporate Announcements

  • Stevanato Group S.p.a. Dividends September,2024

    In the quarter ending September,2024. Stevanato Group S.p.a. has declared dividend of $0.05

    Read More

Company Information

founded in 1949, stevanato group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. it is comprised of two operational divisions: - pharmaceutical systems (ompi and balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. - engineering systems (spami, optrel, innoscan and svm brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. these two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that stevanato group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. the group also benefits from the sglab activ

Organization
Stevanato Group S.p.a.
Employees
5635
CEO
Mr. Franco Stevanato
Industry
Basic Materials

Discover More

FAQs